Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON45797
NL-OMON45797RecruitingNot Applicable

Do mutations in the TBL1X gene alter sensitivity to thyroid hormone? - Mutations inTBL1X and sensitivity to thyroid hormone

Academisch Medisch Centrum0 sites20 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
20
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
2 to 99 (—)

Inclusion Criteria

  • •Isolated central hypothyroidism (low serum FT4, normal TSH concentration) caused by a mutation in the TBL1X gene,
  • •First- or second-degree relative of a patient with central hypothyroidism caused by a mutation in the TBL1X gene, NOT carrying a TBL1X mutation.

Exclusion Criteria

  • •Carriers of other genetic defects known to cause isolated central hypothyroidism.

Investigators

Similar Trials

Completed
Not Applicable
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani PopulationHyperlipidemias
NCT06674044Riphah International University100
Completed
Not Applicable
Differentiation of mutations in toll-like receptors 2 and 4 and their correlation to the classic and modern infect parameters in critically ill patientsA41Other sepsisCritically ill patientsR57.2Septic shock
DRKS00003171niv.-Klinik für Anästhesiologie m.S. operative Intensivmedizin, CVK/CCMCharité-Universitätsmedizin Berlin149
Completed
Not Applicable
Association between SNP of Toll-like receptor 1 (TLR1) and the success rate of Hp erdicatioPatients with Hp infection
JPRN-UMIN000012703Chiba Univerisity100
Recruiting
Not Applicable
Study on influence of UBXD8 gene polymorphism on the pathogenesis of chronic liver diseasesChronic liver disease
JPRN-UMIN000045767agoya University Hospital180
Active, not recruiting
Phase 1
The effects of Tamoxifen on the disease course of patients with Myeloproliferative NeoplasmsMyeloproliferative NeoplasmsMedDRA version: 20.0Level: LLTClassification code 10028576Term: Myeloproliferative disorderSystem Organ Class: 100000004864
EUCTR2015-005497-38-GBniversity of Birmingham